STOCK TITAN
  1. Home
  2. News
  3. EBS

Emergent Biosolutions Inc - EBS STOCK NEWS

Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.

Emergent BioSolutions Inc (NYSE: EBS) is a leader in developing medical countermeasures for public health threats, with a focus on biodefense and emergency response solutions. This page provides investors and stakeholders with centralized access to official press releases, regulatory updates, and strategic developments from the life sciences innovator.

Discover timely updates on key initiatives including NARCAN distribution, government contract awards, and advancements in vaccine manufacturing. Our curated news collection covers earnings reports, partnership announcements, and progress on treatments addressing biological threats like anthrax and smallpox.

Stay informed about Emergent's role in global health security through updates on FDA submissions, manufacturing facility expansions, and collaborations with agencies like BARDA. Content is organized chronologically for easy tracking of operational milestones and financial performance.

Bookmark this page for direct access to verified corporate communications and analysis of how EBS navigates complex regulatory environments while maintaining its position as a critical partner in national preparedness programs.

News

Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

Rhea-AI Summary
Emergent BioSolutions announces appointment of Neal Fowler and Don DeGolyer to its Board of Directors, bringing extensive biopharmaceutical industry and sales experience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.06%
Tags
management acquisition
-
News

Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency

Rhea-AI Summary
Emergent ships NARCAN® Naloxone HCl Nasal Spray to stores and online retailers, priced at $44.99. It will be available nationwide in September. Access to NARCAN® Nasal Spray helps respond to opioid emergencies and save lives. Emergent has not raised the price since 2016 and has lowered the public interest price to $41.00. Almost 17 million doses of naloxone were distributed in the U.S. in 2021.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.55%
Tags
acquisition
-
News

Emergent BioSolutions Reports Financial Results for Second Quarter 2023

Rhea-AI Summary
Emergent BioSolutions reports Q2 2023 total revenues of $338M, net loss of $261M, and adjusted EBITDA of $56M. The company updates its FY 2023 guidance and provides an initial Q3 2023 forecast for total revenues. It also announces strategic steps to reduce investment in and de-emphasize focus on growth in its CDMO business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.78%
Tags
acquisition earnings
News

Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position

Rhea-AI Summary
Emergent BioSolutions (NYSE: EBS) is refocusing its business on core products such as medical countermeasures and NARCAN Nasal Spray. This strategic shift will lead to cost savings of over $100 million annually and a reduction of approximately 400 employees. The company is also eliminating the COO role and is expecting to incur costs of approximately $19 million - $21 million in the third quarter of 2023. Emergent has recently achieved key strategic milestones, including securing contracts with the U.S. government and FDA approval for NARCAN Nasal Spray to be available over-the-counter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
acquisition
-
News

Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola

Rhea-AI Summary
Emergent BioSolutions Inc. has been awarded a 10-year contract by BARDA valued at up to $704 million for the development, manufacturing, and procurement of Ebanga™, a treatment for Ebola virus disease. The contract includes a base period of performance and option periods for advanced development and procurement over five years. Emergent will work on post-licensure commitments and technology transfer as part of manufacturing scale-up.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.97%
Tags
acquisition
-
News

Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023

Rhea-AI Summary
Emergent BioSolutions Inc. (NYSE: EBS) will hold a conference call on August 8, 2023, to discuss second-quarter financial results, recent business developments, revenue guidance for Q3 2023, and financial outlook for full year 2023. Participants can join via webcast or telephone, with a replay available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
acquisition earnings
News

Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Rhea-AI Summary
Emergent BioSolutions Inc. announced that the U.S. FDA has approved CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis. The vaccine has been delivered to the U.S. Department of Health and Human Services since 2019 and will continue to be procured post-approval. CYFENDUS™ vaccine is a component of the U.S. government’s preparedness efforts against anthrax, a high-priority national security threat.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.37%
Tags
acquisition fda approval
-
News

Emergent BioSolutions Announces CEO Transition

Rhea-AI Summary
Emergent BioSolutions announced the retirement of Robert G. Kramer Sr. as President and CEO, with Haywood Miller appointed as interim CEO. The company will conduct a search for a new permanent CEO. Kramer will serve as an advisor until August 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.95%
Tags
acquisition
-
News

Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
acquisition
News

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
acquisition
Stock EBS logo
Emergent Biosolutions Inc

NYSE:EBS

EBS Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

EBS Stock Data

290.97M
53.04M
3.1%
64.59%
14.97%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
GAITHERSBURG